232 related articles for article (PubMed ID: 27123846)
1. Increased Circulating Levels of Alpha-Ketoglutarate in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Armengol S; Sabench F; Ras R; Hernandez M; Aguilar C; Colom J; Sirvent JJ; Del Castillo D; Richart C
PLoS One; 2016; 11(4):e0154601. PubMed ID: 27123846
[TBL] [Abstract][Full Text] [Related]
2. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease.
Rodríguez-Gallego E; Guirro M; Riera-Borrull M; Hernández-Aguilera A; Mariné-Casadó R; Fernández-Arroyo S; Beltrán-Debón R; Sabench F; Hernández M; del Castillo D; Menendez JA; Camps J; Ras R; Arola L; Joven J
Int J Obes (Lond); 2015 Feb; 39(2):279-87. PubMed ID: 24675715
[TBL] [Abstract][Full Text] [Related]
3. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
4. Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.
Paredes-Turrubiarte G; González-Chávez A; Pérez-Tamayo R; Salazar-Vázquez BY; Hernández VS; Garibay-Nieto N; Fragoso JM; Escobedo G
Clin Exp Med; 2016 May; 16(2):193-202. PubMed ID: 25894568
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive Evaluation of NAFLD with Indocyanine Green Clearance Test: a Preliminary Study in Morbidly Obese Patients Undergoing Bariatric Surgery.
Danin PE; Anty R; Patouraux S; Raucoules-Aimé M; Gugenheim J; Tran A; Gual P; Iannelli A
Obes Surg; 2018 Mar; 28(3):735-742. PubMed ID: 28875438
[TBL] [Abstract][Full Text] [Related]
6. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
[TBL] [Abstract][Full Text] [Related]
8. Circulating microbiota-derived metabolites: a "liquid biopsy?
Aragonès G; Colom-Pellicer M; Aguilar C; Guiu-Jurado E; Martínez S; Sabench F; Antonio Porras J; Riesco D; Del Castillo D; Richart C; Auguet T
Int J Obes (Lond); 2020 Apr; 44(4):875-885. PubMed ID: 31388096
[TBL] [Abstract][Full Text] [Related]
9. Transaminase Concentrations Cannot Separate Non-Alcoholic Fatty Liver and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients Irrespective of Histological Algorithm.
Lemmer P; Selbach N; Baars T; Porsch-Özcürümez M; Heider D; Canbay A; Sowa JP
Dig Dis; 2022; 40(5):644-653. PubMed ID: 34469884
[TBL] [Abstract][Full Text] [Related]
10. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
12. Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.
Auguet T; Berlanga A; Guiu-Jurado E; Martinez S; Porras JA; Aragonès G; Sabench F; Hernandez M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2014 Dec; 15(12):22173-87. PubMed ID: 25474087
[TBL] [Abstract][Full Text] [Related]
13. Novel circulating biomarkers for non-alcoholic fatty liver disease: A systematic review.
Sahebkar A; Sancho E; Abelló D; Camps J; Joven J
J Cell Physiol; 2018 Feb; 233(2):849-855. PubMed ID: 28063221
[TBL] [Abstract][Full Text] [Related]
14. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Polyzos SA; Aronis KN; Kountouras J; Raptis DD; Vasiloglou MF; Mantzoros CS
Diabetologia; 2016 Jan; 59(1):30-43. PubMed ID: 26407715
[TBL] [Abstract][Full Text] [Related]
15. miR33a/miR33b* and miR122 as Possible Contributors to Hepatic Lipid Metabolism in Obese Women with Nonalcoholic Fatty Liver Disease.
Auguet T; Aragonès G; Berlanga A; Guiu-Jurado E; Martí A; Martínez S; Sabench F; Hernández M; Aguilar C; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669236
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease.
Hendy OM; Elsabaawy MM; Aref MM; Khalaf FM; Oda AMA; El Shazly HM
APMIS; 2017 Jul; 125(7):607-613. PubMed ID: 28430371
[TBL] [Abstract][Full Text] [Related]
17. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients.
García-Galiano D; Sánchez-Garrido MA; Espejo I; Montero JL; Costán G; Marchal T; Membrives A; Gallardo-Valverde JM; Muñoz-Castañeda JR; Arévalo E; De la Mata M; Muntané J
Obes Surg; 2007 Apr; 17(4):493-503. PubMed ID: 17608262
[TBL] [Abstract][Full Text] [Related]
18. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis.
Hohenester S; Christiansen S; Nagel J; Wimmer R; Artmann R; Denk G; Bischoff M; Bischoff G; Rust C
Am J Physiol Gastrointest Liver Physiol; 2018 Sep; 315(3):G329-G338. PubMed ID: 29878845
[TBL] [Abstract][Full Text] [Related]
19. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans.
Männistö VT; Simonen M; Hyysalo J; Soininen P; Kangas AJ; Kaminska D; Matte AK; Venesmaa S; Käkelä P; Kärjä V; Arola J; Gylling H; Cederberg H; Kuusisto J; Laakso M; Yki-Järvinen H; Ala-Korpela M; Pihlajamäki J
Liver Int; 2015 Jul; 35(7):1853-61. PubMed ID: 25533197
[TBL] [Abstract][Full Text] [Related]
20. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis.
Cabré N; Luciano-Mateo F; Baiges-Gayà G; Fernández-Arroyo S; Rodríguez-Tomàs E; Hernández-Aguilera A; París M; Sabench F; Del Castillo D; López-Miranda J; Menéndez JA; Camps J; Joven J
Aliment Pharmacol Ther; 2020 Feb; 51(3):374-387. PubMed ID: 31825539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
